Kenvue Defends ORSL, ERZL Amid Misinformation Concerns, Reaffirms Science-Backed Hydration Strategy

The company stated that it has worked closely with healthcare professionals and medical associations for decades to improve health outcomes and contribute to scientific literature across product categories, both globally and in India. It emphasized that its hydration portfolio has been developed in compliance with all applicable laws and regulatory provisions.

Kenvue highlighted its long-standing role in shaping the hydration category in India through scientifically formulated solutions. The company noted that it has contributed to evidence-based research, resulting in peer-reviewed publications in indexed journals and presentations at major medical conferences such as PEDICON, APICON, FMPC and RSSDI.

However, the company expressed concern over “continuous disparagement” of its brands ORSL and ERZL, along with claims regarding sucralose, stating that such narratives have led to confusion and fear among consumers.

As part of its portfolio strategy, Kenvue said it introduced a dual-brand approach in January 2026. Under this, ORSL has been positioned as a drug product aligned with WHO Oral Rehydration Solution standards for the treatment of diarrheal dehydration, while ERZL has been developed as a food product catering to everyday hydration needs such as fatigue, heat exhaustion and general tiredness.

The company maintained that it has followed a transparent and responsible communication approach, ensuring that consumers are clearly informed about the appropriate use of each product. It also said it continues to engage with healthcare professionals, chemists and other stakeholders through educational initiatives to promote informed decision-making.

Kenvue further noted that it has reformulated its ERZL electrolyte drinks portfolio to better align with evolving health priorities. According to the company, the updated formulation contains 87% less added sugar and offers 1.4 times more electrolytes, positioning it as a category-first move aimed at supporting efforts to reduce sugar intake and address non-communicable diseases.

Addressing concerns around sucralose, the company stated that the ingredient has undergone extensive scientific evaluation and is recognized as safe by global and Indian regulatory bodies, including Codex, the European Food Safety Authority (EFSA), the Food Safety and Standards Authority of India (FSSAI), and the Central Drugs Standard Control Organisation (CDSCO). It also clarified that WHO’s 2023 guidelines on non-sugar sweeteners relate to weight management and do not apply to products such as WHO ORS or electrolyte drinks.

While reiterating its commitment to scientific dialogue, Kenvue said it had attempted to engage with individuals raising concerns but received no response. The company added that it has taken necessary steps to safeguard its brand integrity and prevent the spread of misinformation.

Kenvue emphasized that it remains committed to collaborating with the healthcare and scientific community to advance public health initiatives and promote evidence-based practices.